270 related articles for article (PubMed ID: 23014900)
1. Five-year follow-up of the ABSORB bioresorbable everolimus-eluting vascular scaffold system: multimodality imaging assessment.
García-García HM; Schultz C; Duckers E; Regar E; Ligthart J; Serruys PW; van Geuns RJ
EuroIntervention; 2013 Feb; 8(10):1126-7. PubMed ID: 23014900
[No Abstract] [Full Text] [Related]
2. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial.
Onuma Y; Serruys PW; Ormiston JA; Regar E; Webster M; Thuesen L; Dudek D; Veldhof S; Rapoza R
EuroIntervention; 2010 Sep; 6(4):447-53. PubMed ID: 20884431
[TBL] [Abstract][Full Text] [Related]
3. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
[TBL] [Abstract][Full Text] [Related]
4. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.
Gogas BD; Serruys PW; Diletti R; Farooq V; Brugaletta S; Radu MD; Heo JH; Onuma Y; van Geuns RJ; Regar E; De Bruyne B; Chevalier B; Thuesen L; Smits PC; Dudek D; Koolen J; Windecker S; Whitbourn R; Miquel-Hebert K; Dorange C; Rapoza R; Garcia-Garcia HM; McClean D; Ormiston JA
JACC Cardiovasc Interv; 2012 Jun; 5(6):656-65. PubMed ID: 22721662
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.
Serruys PW; Onuma Y; Garcia-Garcia HM; Muramatsu T; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Ormiston JA
EuroIntervention; 2014 Mar; 9(11):1271-84. PubMed ID: 24291783
[TBL] [Abstract][Full Text] [Related]
6. Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH).
Simsek C; Magro M; Onuma Y; Boersma E; Smits P; Dorange C; Veldhof S; Regar E; Serruys PW; van Geuns RJ
EuroIntervention; 2014 Jun; 10(2):236-40. PubMed ID: 23999210
[TBL] [Abstract][Full Text] [Related]
7. Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial.
Brugaletta S; Gomez-Lara J; Serruys PW; Farooq V; van Geuns RJ; Thuesen L; Dudek D; Koolen J; Chevalier B; McClean D; Windecker S; Smits PC; de Bruyne B; Whitbourn R; Meredith I; van Domburg RT; Sihan K; de Winter S; Veldhof S; Miquel-Hebert K; Rapoza R; Garcia-Garcia HM; Ormiston JA; Bruining N
JACC Cardiovasc Interv; 2011 Dec; 4(12):1281-9. PubMed ID: 22192369
[TBL] [Abstract][Full Text] [Related]
8. Bailout left main bioresorbable vascular scaffolding for the treatment of iatrogenic coronary dissection induced by guiding catheter and sticky ABSORB bioresorbable vascular scaffold balloon.
Yew KL
Int J Cardiol; 2015; 187():527-9. PubMed ID: 25846666
[No Abstract] [Full Text] [Related]
9. Side branch occlusion after bioresorbable vascular scaffold implantation: lessons from optimal coherence tomography.
Sato K; Panoulas VF; Kawamoto H; Naganuma T; Miyazaki T; Latib A; Colombo A
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):116-8. PubMed ID: 25616826
[No Abstract] [Full Text] [Related]
10. Everolimus-eluting bioabsorbable stent--Abbot Vascular programme.
Onuma Y; Piazza N; Ormiston JA; Serruys PW
EuroIntervention; 2009 Dec; 5 Suppl F():F98-F102. PubMed ID: 22100687
[No Abstract] [Full Text] [Related]
11. Vascular compliance changes of the coronary vessel wall after bioresorbable vascular scaffold implantation in the treated and adjacent segments.
Brugaletta S; Gogas BD; Garcia-Garcia HM; Farooq V; Girasis C; Heo JH; van Geuns RJ; de Bruyne B; Dudek D; Koolen J; Smits P; Veldhof S; Rapoza R; Onuma Y; Ormiston J; Serruys PW
Circ J; 2012; 76(7):1616-23. PubMed ID: 22531596
[TBL] [Abstract][Full Text] [Related]
12. No more metallic cages: an attractive hybrid strategy with bioresorbable vascular scaffold and drug-eluting balloon for diffuse or tandem lesions in the same vessel.
Naganuma T; Latib A; Ielasi A; Panoulas VF; Sato K; Miyazaki T; Colombo A
Int J Cardiol; 2014 Apr; 172(3):618-9. PubMed ID: 24495653
[No Abstract] [Full Text] [Related]
13. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA
J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884
[TBL] [Abstract][Full Text] [Related]
14. [Structure and function of the fully bioresorbable vascular scaffold].
De Servi S
G Ital Cardiol (Rome); 2013 Sep; 14(9 Suppl 1):4S-7S. PubMed ID: 24084667
[No Abstract] [Full Text] [Related]
15. A case of true left main bifurcation treated with bioresorbable everolimus-eluting stent v-stenting.
Sato K; Latib A; Panoulas VF; Naganuma T; Miyazaki T; Colombo A
JACC Cardiovasc Interv; 2014 Aug; 7(8):e103-4. PubMed ID: 25086841
[No Abstract] [Full Text] [Related]
16. Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial.
Sarno G; Bruining N; Onuma Y; Garg S; Brugaletta S; De Winter S; Regar E; Thuesen L; Dudek D; Veldhof S; Dorange C; Garcia-Garcia HM; Ormiston JA; Serruys PW
Int J Cardiovasc Imaging; 2012 Jan; 28(1):51-8. PubMed ID: 21213050
[TBL] [Abstract][Full Text] [Related]
17. Optical coherence tomography imaging of everolimus-eluting bioresorbable vascular scaffold implanted into coronary vein graft at 3-month follow-up.
Roleder T; Parma Z; Smolka G; Ochała A; Wojakowski W
Eur Heart J; 2014 Sep; 35(33):2207. PubMed ID: 24722807
[No Abstract] [Full Text] [Related]
18. Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: a sub-study of the ABSORB Cohort B and the on-going ABSORB EXTEND Single Arm Study.
Farooq V; Gomez-Lara J; Brugaletta S; Gogas BD; Garcìa-Garcìa HM; Onuma Y; van Geuns RJ; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW
Catheter Cardiovasc Interv; 2012 May; 79(6):880-8. PubMed ID: 22514149
[TBL] [Abstract][Full Text] [Related]
19. The ABSORB bioresorbable vascular scaffold: A novel, fully resorbable drug-eluting stent: Current concepts and overview of clinical evidence.
Rizik DG; Hermiller JB; Kereiakes DJ
Catheter Cardiovasc Interv; 2015 Oct; 86(4):664-77. PubMed ID: 26386235
[TBL] [Abstract][Full Text] [Related]
20. Treatment of coronary bifurcation lesions with bioresorbable vascular scaffolds.
Capranzano P; Gargiulo G; Capodanno D; Longo G; Tamburino C; Ohno Y; Attizzani GF; La Manna A; Di Salvo M; Francaviglia B; Grasso C; Sgroi C; Tamburino C
Minerva Cardioangiol; 2014 Jun; 62(3):229-34. PubMed ID: 24831758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
